<DOC>
	<DOCNO>NCT01066819</DOCNO>
	<brief_summary>This observational study ass predictor early on-treatment sustained virological response treatment-naïve patient chronic hepatitis C initiate treatment Pegasys ( peginterferon alfa-2a ) peginterferon alfa-2b ribavirin . Data collect treatment period ( 24 48 week ) 12 24 week end treatment . Target sample size &lt; 2000 .</brief_summary>
	<brief_title>PROPHESYS 3 : Observational Study Predictors Response Patients With Treatment-naïve Chronic Hepatitis C Initiated Treatment With Pegasys ( Peginterferon Alfa-2a ) Peginterferon-alfa-2b</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>adult patient , &gt; /= 18 year age chronic hepatitis C HIV HCV coinfection allow informed consent data collection coinfection Hepatitis B Virus ( HBV ) previous treatment peginterferon and/or ribavirin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>